v3.25.4
Segment information (Tables)
9 Months Ended
Dec. 31, 2025
Segment Reporting [Abstract]  
Schedule of Financial Information Including Significant Segment Expenses by Program
The following table presents selected financial information with respect to the Company's single operating segment, including significant segment expenses by program, for the three and nine months ended December 31, 2025 and 2024:
Three Months Ended
December 31,
Nine Months Ended
December 31,
2025202420252024
Operating expenses:(Amounts in thousands)
Direct research and development expenses by program:
RP1 program costs by study:
IGNYTE2,059 3,226 8,073 10,831 
ARTACUS1,663 1,787 4,898 5,211 
CERPASS1,012 1,611 3,653 5,573 
IGNYTE-34,219 2,375 15,554 4,909 
Other RP1 study costs5,200 1,590 15,162 7,075 
RP27,729 4,409 16,857 8,322 
RP3826 1,434 2,262 3,856 
Unallocated research and development expenses¹:30,432 31,572 102,401 89,695 
Selling, general and administrative18,728 18,015 77,721 46,827 
Total operating expenses71,868 66,019 246,581 182,299 
Loss from operations(71,868)(66,019)(246,581)(182,299)
Other income (expense), net627 $254 $5,547 $9,707 
Loss before income taxes$(71,241)$(65,765)$(241,034)$(172,592)
Income tax (benefit) provision
(311)575 (311)575 
Net loss(70,930)(66,340)(240,723)(173,167)
1Includes personnel-related costs and other costs